Boehringer Ingelheim has three oral compounds for the treatment of diabetes type II in phase II and III of clinical development. The most advanced compound, a DPP-4 inhibitor, is currently in the final clinical phase.
In contrast to other substances in this compound class, phase IIb studies revealed an excellent safety profile for DPP-4 (dipeptidylpeptidase inhibitors) which is currently being tested in broad clinical phase III studies to assess the safety and efficiency in the long-term use of the drug. Two more anti-diabetes drugs with another mode of action, so-called SGLT-2 inhibitors, are currently being tested in phase II clinical trials.In 2001, Boehringer started focusing on novel treatment options for patients suffering from diabetes type 2. Besides oncology, diabetes is the company’s second new therapeutic field within the past few years. In November 2006, Boehringer Ingelheim announced their cancer drug development programme.